CN Patent

CN107698562A — 一种喹啉衍生物及其用途

Assigned to Individual · Expires 2018-02-16 · 8y expired

What this patent protects

本发明涉及一种新型的喹啉衍生物、其可药用盐、水合物或以任何形式代谢形成的代谢产物，及在制备预防和/或治疗与血管生成有关的适应症的药物中的用途。本发明的喹啉衍生物是理想的高效VEGFR抑制剂，可用于治疗或预防肿瘤生长，以及其他与血管生成相关的转移生长疾病。

USPTO Abstract

本发明涉及一种新型的喹啉衍生物、其可药用盐、水合物或以任何形式代谢形成的代谢产物，及在制备预防和/或治疗与血管生成有关的适应症的药物中的用途。本发明的喹啉衍生物是理想的高效VEGFR抑制剂，可用于治疗或预防肿瘤生长，以及其他与血管生成相关的转移生长疾病。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN107698562A
Jurisdiction: CN
Classification: —
Expires: 2018-02-16
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.